Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when funding or meeting opportunities are announced please click on the link below.

Sign up for new announcements.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research support through the BrightFocus Foundation (www.brightfocus.org). Please follow instructions on the notification emails for removal requests.

 
 
BrightFocus Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

 

Macular Degeneration Research
Completed Award

Dr. Bruce Ksander

Bruce Ksander, Ph.D.

The Schepens Eye Research Institute
Boston, MA, United States

Title: NALP3 Activation Triggers Development of AMD
Non-Technical Title: Inflammation as a Trigger of Age Related Macular Degeneration

Duration: July 1, 2011 - June 30, 2013
Award Type: Standard
Award Amount: $99,836

Summary:

Age related Macular Degeneration (AMD) causes loss of vision and blindness in elderly patients when two types of cells are damaged (i) RPE (called retinal pigment epithelial cells), and (ii) photoreceptors. We discovered a gene (called NALP3) is expressed in retinal cells during development of AMD. We predict this gene is important in triggering this disease via the activation of localized inflammation.

Details:

Retinal pigment epithelial (RPE) cells support the light‐detecting photoreceptor cells by recycling and removing waste products. If RPE cells are unhealthy, then this waste can build‐up and damage the retina. Inflammation is an important part of the AMD disease process, and RPE cells have their own special type of proteins—called the “inflammasome”—to monitor and determine if the RPE are working properly. In fact, if this RPE waste recycling and removal process isn't functioning properly, the inflammasome sends out signals for the immune system to swoop in and kill the malfunctioning RPE cells. Dr. Ksander and collaborators have discovered a new risk gene—called NALP3— that is expressed in retinal cells and is suspected to be important in triggering AMD via the inflammasome. These researchers will determine whether this gene is involved in the death of RPE cells and, if so, whether it will be a new target for treatment of AMD.

Publications:

Tseng WA, Thein T, Kinnunen K, Lashkari K, Gregory MS, D'Amore PA, Ksander BR. NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: implications for age-related macular degeneration. Invest Ophthalmol Vis Sci. 2013 Jan 7;54(1):110-20. doi: 10.1167/iovs.12-10655. PubMed Icon Google Scholar Icon